cancel
Showing results for 
Search instead for 
Did you mean: 

Weekly Blog: The use of artificial intelligence to determine cancer recurrence

PCFA_OC_Manager
Community Manager
Community Manager
0 0 115

AI detect banner.jpg

 

By Kalli Spencer

Following a radical prostatectomy there is always a risk that cancer may recur. Certain factors may increase this risk such as high-grade features on the initial biopsy specimen, cancer that may have evaded outside the prostate capsule, micrometastases (cancer that cannot be picked up with any imaging), technical difficulties in surgery or no explanation at all other than the genetic makeup of the cancer in a particular individual which gives it the propensity to grow and invade. In its efforts to survive, the cancer develops several mechanisms to evade the bodies immune system and can even resist the effects of treatment. The genetics behind this is still largely unknown. But the scientists are on it and success has been seen in other tumours such as colon and stomach cancer. A team from the University of Wisconsin in the United States have developed a unique diagnostic test which utilises artificial intelligence to detect genetic abnormalities and determine which patients’ prostate cancer is more likely to recur and progress and hence guide earlier treatment options.

Features at the cell level and molecular level (within the cells) in prostate cancer formation and progression in each patient are different and complex. This complicates the development of clinically relevant biomarkers (blood tests) and the timing and sequence determination for drug selection strategies to beat the cancer at its own game. Recent research has elucidated that there is a complex interaction between cancer cells and cells and molecules in between them, known as the tumour micro-environment. Within this environment are immune cells that are being targeted by the cancer (the degree of which varies between individuals) preventing itself from being destroyed. 

These complex processes cannot be visualised by the human eye glancing down a microscope at a glass slide (rectangular piece of thin glass where the small piece of prostate tissue sits). They require more advanced analysis techniques. Huang et al have created a digital whole slide image (WSI) of the prostate tissue which is stored in a computer. This is where it gets complex: specialised artificial intelligence software is able to extract subvisual features of the cancer cells using deep convolutional neural networks (DCNNs). The task of predicting outcomes from WSI is particularly challenging because of the large size of these images (approximately 100,000 × 100,000 pixels) and the fact that the unusual cell features associated with adverse outcomes, which are also unknown at this point, could be present in any part of the imaged tissue. 

Until now only a few biomarkers that can be used to guide treatment of prostate cancer using molecular biology and bioinformatics have been discovered and researched. These include molecular markers, such as Ki-67, p53, MYC, PTEN, Rb, AR, and ERG. Knowing that a patient’s cancer has these biomarkers may help stratify their cancer risk profile but also determine the chance of tumour recurrence. Currently these molecular markers have been combined with the traditional Gleeson Grading system to create scoring systems that can help determine a patient’s prognosis. DECIPHER, POLARIS, Oncotype Dx are currently being researched in other clinical trials. Preliminary clinical trial findings suggests that most of these genome-based scores, however, only marginally improve the prognostic accuracy of Gleeson Grade scoring at present. Traditional tissue processing techniques in the laboratory have made the identification of biomarkers challenging. 

Results of trials looking at cancer treatment have shown that the application of newer therapies sooner in the prostate cancer disease course have improved patient outcomes. Well known clinical trials such as PROSPER, SPARTAN, and ARAMIS where drugs such as enzalutamide, apalutamide, or darolutamide, respectively, are added to standard androgen deprivation therapy have demonstrated improvements in multiple clinical outcomes including overall survival; time to develop metastases; time taken for the prostate specific antigen (PSA) to rise in the blood; and time to the initiation of chemotherapy.

Moving to an earlier state of prostate cancer, the TITAN trial examined the addition of apalutamide for metastatic castration sensitive cancer (usually reserved for castrate resistant cancer) demonstrating an advantage for the addition of this drug. The STAMPEDE trials showed improved outcomes with the addition of radiation in patients with low volume metastatic disease. Therefore, it is of paramount importance to be able to stratify prostate cancer patients who are at risk of recurrence for targeted therapy in a timely fashion to improve their survival.

The authors new technology which utilises artificial intelligence to detect specific features within the cells of prostate cancer will lead to the discovery of new biomarkers which will help identify those at risk of recurrence and improve outcomes.

Reference:

American Society of Clinical Oncology

Huang W et al. A novel artificial intelligence – powered method for prediction of early recurrence of prostate cancer after prostatectomy and cancer drivers. Journal of Clinical Oncology. Clinical Cancer Informatics 2022. 6(e2100131)  


About the Author

kalli-spencer.jpeg

Kalli Spencer

MBBCh, FC Urol (SA), MMed (Urol), Dip.Couns (AIPC)

Kalli is an internationally renowned Urological Surgeon, specialising in oncology and robotic surgery. He trained and worked in South Africa, before relocating to Australia where he has worked at Macquarie University Hospital and Westmead Hospital. His passion for what he does extends beyond the operating room, through public health advocacy, education and community awareness of men’s health, cancer and sexuality.

Kalli has been involved with the Prostate Cancer Foundation of Australia for many years, advocating for improved cancer care and facilitating community prostate cancer support groups.


Help is Available

Prostate Cancer Specialist Telenursing Service

If your life has been impacted by prostate cancer, our Specialist Telenursing Service is available to help. If you would like to reach out to the PCFA Prostate Cancer Specialist Telenurse Service for any questions you have about your prostate cancer experience, please phone 1800 22 00 99 Monday - Friday 9am - 5pm, Wednesday 10am-8pm (AEST).

Prostate Cancer Support Groups

PCFA is proud to have a national network of affiliated support groups in each state and territory of Australia consisting of men and women who have a passion for assisting others who encounter prostate cancer. This network is made up of over 170 affiliated groups who meet locally to provide one-to-one support, giving a vision of life and hope after treatment. Call us on 1800 22 00 99 to find your local group.

MatesCONNECT Telephone-based peer support

MatesCONNECT is a telephone-based peer support program for men affected by prostate cancer. If you’ve recently been diagnosed with prostate cancer, our MatesCONNECT service can connect you to a trained volunteer who understands what you’re going through. All of our volunteers have been through prostate cancer. Simply call us on 1800 22 00 99 to be connected with a volunteer.

Newly diagnosed? or need to find more information? Access the PCFA resources here.

House Rules

To help keep this community a welcoming, supportive and caring place we have put together a small list of dos and don'ts for you to think about when posting on our forum, research blog or video gallery. For further information please see our  terms and conditions.

Adhere to PCFA’s five core values of Integrity, Optimism, Compassion, Respect and Commitment.

Our online forum is for you to share experiences with others and does not contain specific medical, counselling or legal advice.  If you require professional advice specific to your individual circumstances we encourage you to see a medical professional, legal professional or counsellor.

No commercial or promotional activity. While members may share information about resources they have found helpful, the PCFA Online Community forum should not be used for the promotion of goods and services. This includes commercial entities passing themselves off as individuals and people who frequently post links to external health professionals or other services.

Be kind to each other - many people using the community are going through a difficult time. A few kind words can go a long way. Please welcome new posters – it can be very nerve-wracking to post on the forum for the first time.

If you or someone you know is suffering from mental health issues, such as depression or anxiety, we encourage you to seek assistance and contact Beyond Blue Tel:1300 224 636 or Lifeline Tel:13 11 14

Speak your mind freely, but please be sensitive to the feelings and experiences of others - you might not always agree, but you can agree to disagree in a peaceful manner.

Don't use offensive language -if a user is found to be using offensive language during their conversations the moderators reserve the right to edit the thread, without warning.

Don't use all capital letters in your posts - it's considered ‘shouting' online and it makes posts difficult to read.

Give each other the benefit of the doubt - please remember that it is all too easy for the tone and meaning of posts to be misinterpreted. Think carefully before replying to a discussion. it It is important to remember that things written rather than said can feel much stronger, so please bear this in mind when reading other people's messages.

Please respect the moderators - their job is to keep the forum safe and constructive so that everybody gets to have his or her fair say.

Stay on topic - try to focus on the original topic. In particular, don't change subject in the middle of an existing thread - just start a new thread.

Read what's already on the forum before posting - you may be repeating what others have already said or asked.

We want PCFA's Online Community to be a secure and helpful environment for all of the community. So please remember that by using PCFA's Online Community you are agreeing to follow our terms and conditions.